SLAS News (Nov. 9, 2017) — SLAS, the Society for Laboratory Automation and Screening, has announced the three most recent additions to the Society’s nine-member Board of Directors. Each of these new members will serve a three-year term, beginning at SLAS2018, starting February 3 at the San Diego Convention Center in San Diego, California, USA. The three new members of the SLAS Board of Directors are:
Emilio Diez Monedero
Chief Scientific Officer
ATLAS Molecular Pharma & Drug Discovery Consultant, Madrid, Spain
Emilio Diez Monedero is an executive leader with more than 30 years of drug discovery experience. He is currently focused in the transition of new ideas from Academia to Industry by facilitating and driving collaborations between academic laboratories, not-for-profit organizations and small- and medium-sized enterprises. Diez Monedero has served SLAS in numerous volunteer roles including journal author, conference presenter, SLAS Europe Council and SLAS Governance Task Force. He is co-chair of the first SLAS European conference, to be held June 27-29, 2018 in Brussels, Belgium. Diez Monedero earned his Ph.D. in biochemistry from Universidad Complutense de Madrid, Madrid, Spain.
“I strongly believe that SLAS has played a key role in the transformation of how Biomedical Research is performed today in our laboratories,” says Diez Monedero. “Moreover, educational content from SLAS has helped many academics, industry scientists and technologists develop their careers and strengthen their professional networks. I am very excited to give back to Society by way of serving on its Board of Directors. I look forward to lending my experience, insights and connections to help the Society fulfill its mission and improve the value it provides to all of its key stakeholders.”
Peter Brian Simpson
Chief Scientific Officer
Medicines Discovery Catapult, Alderley Park, UK
With a longstanding commitment to innovation and collaboration in early drug discovery, Peter Simpson has held numerous drug discovery leadership roles throughout his career. Passionate about disruptive, collaborative innovation to secure new medicines for patients, Simpson supports Medicines Discovery Catapult’s mission to act as champion for drug discovery and technology small- and medium-sized enterprises. An active SLAS contributor, Simpson currently serves as reviews editor for SLAS Discovery,
commissioning insightful reviews on new drug targets and technology advances. Simpson earned a Ph.D. in cell physiology and pharmacology from the University of Leicester, Leicester, UK.
“As the largest international network of its kind, SLAS represents individuals at the forefront of global scientific innovation,” says Simpson. “The life sciences research community is moving into an exciting era of closer collaboration across institutional boundaries, enabling new models for drug discovery and technology innovation. I’m delighted to be joining SLAS’s Board of Directors at this pivotal time. I look forward to working with colleagues to drive the strategy of SLAS, helping researchers learn about and respond rapidly to new opportunities, which will lead to the research breakthroughs of the future.”
Co-Founder and Managing Partner
Novoptim, Montigny le Bretonneux, France
Severine Tamas-Lhoustau is a seasoned executive with more than 20 years of experience in business development and sales and marketing in the drug discovery and life sciences arena. Novoptim supports innovative start-up companies with strategic positioning, go-to-market strategy and technology launch assistance in the pharmaceutical and biotech markets. She has a proven track record of helping organizations expand into new markets. Tamas-Lhoustau serves on the SLAS Europe Industry Advisory Committee and earned her degree in biotechnology from the Institut National des Sciences Appliquées de Toulouse, Toulouse, France.
Says Tamas-Lhoustau on her election to the SLAS Board: “I am honored to serve on the SLAS Board of Directors. I know firsthand how effective the Society has been at delivering education, insight and peer connection opportunities to members of the life sciences community. Furthermore, I am excited to offer my expertise and industry connections to expand the reach of the Society across the pharmaceutical, biotechnology and academic arenas. I also believe SLAS is poised to better assist entrepreneurial and start up organizations develop state-of-the-art technologies through improved market access, customer feedback and collaboration opportunities. Doing so will enable the Society to fulfill its mission while accelerating important scientific discovery.”
Diez Monedero, Simpson and Tamas-Lhoustau will fill vacancies created by the completion of terms by three SLAS Board members: Scott Atkin, IOI Partners; Michele Cleary, The Mark Foundation for Cancer Research; and Susan M. Lunte, Ralph N. Adams Institute for Bioanalytical Chemistry at the University of Kansas.
The selection process of new Board members was led by the SLAS Nominations Committee. The confirmation process for Diez Monedero, Simpson and Tamas-Lhoustau began with an open call for nominations. In November, final recommendations were approved by the SLAS Board of Directors.
Tom Manning, Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103